Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection.
COVID-19
multiple sclerosis
onset
relapse
vaccine
Journal
Neurology international
ISSN: 2035-8385
Titre abrégé: Neurol Int
Pays: Switzerland
ID NLM: 101551564
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
24
10
2021
revised:
25
11
2021
accepted:
29
11
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with several neurological disorders including headache, facial palsy, encephalitis, stroke, demyelinating disorders. The present report will discuss cases of multiple sclerosis (MS) onset and relapse both beginning early after SARS-CoV-2 infection. In both cases, magnetic resonance imaging (MRI) showed widespread bilateral subcortical and periventricular active lesions. Serum IgG against SARS-CoV-2 Spike antigens confirmed seroconversion with titers that are considered not definitely protective against possible reinfection. We hypothesize that SARS-CoV-2 infection, as previously reported for other viruses, could drive an active inflammatory response that can contribute either to the onset of MS or its relapse. The presented data further support the importance of vaccination in individuals with MS.
Identifiants
pubmed: 34940752
pii: neurolint13040066
doi: 10.3390/neurolint13040066
pmc: PMC8707620
doi:
Types de publication
Case Reports
Langues
eng
Pagination
695-700Références
Ann Neurol. 2019 Sep;86(3):436-442
pubmed: 31226219
J Neurol Neurosurg Psychiatry. 2021 Aug 18;:
pubmed: 34408003
Clin Microbiol Infect. 2021 Mar;27(3):458-466
pubmed: 33189873
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):528-44
pubmed: 22583435
Arch Virol. 2021 Mar;166(3):733-753
pubmed: 33502593
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
Nat Commun. 2021 Jan 4;12(1):63
pubmed: 33397909
Lancet Neurol. 2002 Jul;1(3):145
pubmed: 12849479
Mult Scler Relat Disord. 2021 Feb;48:102698
pubmed: 33385826
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
J Neurol. 2020 Aug;267(8):2179-2184
pubmed: 32458193
Front Neurol. 2021 Feb 26;12:635747
pubmed: 33732209
J Neuroimmune Pharmacol. 2021 Jun;16(2):270-288
pubmed: 33544324
eNeurologicalSci. 2020 Dec;21:100287
pubmed: 33163634
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6107-E6116
pubmed: 28696309
Mult Scler Relat Disord. 2020 Oct;45:102377
pubmed: 32698095
N Engl J Med. 2001 Feb 1;344(5):319-26
pubmed: 11172162
Acta Neurochir (Wien). 2020 Jul;162(7):1491-1494
pubmed: 32367205
J Neurochem. 2016 Feb;136(3):564-72
pubmed: 26499872
J Neurol. 2021 Sep 4;:
pubmed: 34480607
Drug Discov Today Dis Models. 2020 Fall;32:27-33
pubmed: 32292487
Brain. 2002 May;125(Pt 5):952-60
pubmed: 11960885